Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 369 clinical trials
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.

pet-ct scan
carcinoma
esophageal carcinoma
platelet count
metastasis
  • 0 views
  • 26 Mar, 2022
  • 3 locations
AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) visually estimated combined positive score (vCPS) 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.

carcinoma
squamous cell carcinoma
measurable disease
monoclonal antibodies
  • 11 views
  • 22 Nov, 2021
  • 71 locations
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will …

cancer
concurrent chemoradiation
carcinoma
esophagus cancer
esophageal cancer
  • 0 views
  • 04 Jun, 2022
  • 182 locations
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN)

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).

carcinoma
capecitabine
durvalumab
fluorouracil
squamous cell carcinoma
  • 4 views
  • 03 Jul, 2022
  • 83 locations
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or

cancer chemotherapy
oxaliplatin
adenocarcinoma
erbb2
HER2
  • 0 views
  • 30 Jun, 2022
  • 133 locations
Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions

The investigators aim to evaluate the performance of Narrow Band Imaging (NBI) endoscopy in Esophageal Squamous Cell Carcinoma (ESCC) screening, as compared to the currently used White Light Endoscopy (WLE) and Lugol's Iodine Staining Endoscopy (ISE). NBI is a simple, safe and non-invasive technique, which can provide real-time optical staining …

endoscopy
Accepts healthy volunteers
carcinoma
squamous cell carcinoma
  • 0 views
  • 18 Feb, 2022
  • 2 locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

oxaliplatin
carcinoma
adenocarcinoma
esophageal carcinoma
external radiation
  • 62 views
  • 28 Jun, 2022
  • 141 locations
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 …

carcinoma
solid tumour
esophageal carcinoma
metastasis
lung cancer
  • 14 views
  • 13 Jun, 2022
  • 17 locations
A Study of SGN-STNV in Advanced Solid Tumors

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well …

carcinoma
erbb2
esophagus cancer
cancer of the ovary
HER2
  • 0 views
  • 30 May, 2022
  • 15 locations
Onco-primary Care Networking to Support TEAM-based Care (ONE TEAM)

The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a dynamic treatment regimen approach. The investigators propose to randomize 800 adults with newly-diagnosed selected cancers treated …

treatment regimen
solid tumor
lung carcinoma
cardiovascular complications
hypercholesterolemia
  • 0 views
  • 09 Jun, 2022
  • 1 location